Foundry Partners’s Quest Diagnostics DGX Stock Holding History

Foundry Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$17.3M	Sell	102,473 -5,845	-5%	-$960K	0.92%	35
2024 Q4	$16.3M	Buy	+108,318	New	+$16.8M	0.82%	31
2022 Q2	–	Sell	-112,095	Closed	-$15.3M	–	317
2022 Q1	$15.3M	Sell	112,095 -2,450	-2%	-$341K	0.78%	46
2021 Q4	$19.8M	Buy	+114,545	New	+$17.4M	0.7%	44
2016 Q3	–	Sell	-4,800	Closed	-$391K	–	373
2016 Q2	$391K	Sell	4,800 -132,544	-97%	-$10.1M	0.02%	320
2016 Q1	$9.81M	Buy	137,344 +7,714	+6%	+$517K	0.97%	29
2015 Q4	$9.22M	Sell	129,630 -1,825	-1%	-$123K	0.77%	34
2015 Q3	$8.08M	Sell	131,455 -1,175	-0.9%	-$82.1K	0.71%	42
2015 Q2	$9.62M	Sell	132,630 -51,056	-28%	-$3.77M	0.77%	36
2015 Q1	$14.1M	Buy	183,686 +85,856	+88%	+$6.15M	1.18%	16
2014 Q4	$6.56M	Buy	+97,830	New	+$6.17M	0.54%	69

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Foundry Partners's DGX Position: Q1 2025 in Review

Foundry Partners reduced its Quest Diagnostics (DGX) stake by 5.4% in Q1 2025, selling an estimated $960K and leaving 102,473 shares worth $17.3M. The position accounts for 0.92% of the portfolio, ranked #35.

Foundry Partners first reported a position in DGX in Q4 2014 and has held it in 11 quarters since. The position peaked at $19.8M in Q4 2021. 967 funds tracked by Wall St. Rank hold DGX as of Q1 2025.

Foundry Partners held 102,473 shares of Quest Diagnostics worth $17.3M as of Q1 2025.
Foundry Partners sold 5,845 Quest Diagnostics shares in Q1 2025, an estimated $960K.
Quest Diagnostics made up 0.92% of Foundry Partners's portfolio in Q1 2025, its #35 holding.
Foundry Partners first reported a position in Quest Diagnostics in Q4 2014 and has held it in 11 quarters since.
Foundry Partners's Quest Diagnostics position peaked at $19.8M in Q4 2021.
967 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2025.

Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.